SE451427B - Parenteralt administrerbara vattenlosningar med ett fysiologiskt ph och sett att framstella dessa losningar - Google Patents

Parenteralt administrerbara vattenlosningar med ett fysiologiskt ph och sett att framstella dessa losningar

Info

Publication number
SE451427B
SE451427B SE8002714A SE8002714A SE451427B SE 451427 B SE451427 B SE 451427B SE 8002714 A SE8002714 A SE 8002714A SE 8002714 A SE8002714 A SE 8002714A SE 451427 B SE451427 B SE 451427B
Authority
SE
Sweden
Prior art keywords
acid
phospholipids
acetic acid
aryl
propionic acid
Prior art date
Application number
SE8002714A
Other languages
English (en)
Swedish (sv)
Other versions
SE8002714L (sv
Inventor
M Ghyczy
G Ritzmann
A Erdos
E Etschenberg
Original Assignee
Nattermann A & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattermann A & Cie filed Critical Nattermann A & Cie
Publication of SE8002714L publication Critical patent/SE8002714L/
Publication of SE451427B publication Critical patent/SE451427B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8002714A 1979-04-11 1980-04-10 Parenteralt administrerbara vattenlosningar med ett fysiologiskt ph och sett att framstella dessa losningar SE451427B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792914788 DE2914788A1 (de) 1979-04-11 1979-04-11 Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung

Publications (2)

Publication Number Publication Date
SE8002714L SE8002714L (sv) 1980-10-12
SE451427B true SE451427B (sv) 1987-10-12

Family

ID=6068137

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8002714A SE451427B (sv) 1979-04-11 1980-04-10 Parenteralt administrerbara vattenlosningar med ett fysiologiskt ph och sett att framstella dessa losningar

Country Status (14)

Country Link
US (1) US4309421A (fr)
JP (1) JPS55141407A (fr)
AT (1) AT369651B (fr)
AU (1) AU539044B2 (fr)
BE (1) BE882731A (fr)
CA (1) CA1144480A (fr)
CH (1) CH642546A5 (fr)
DE (1) DE2914788A1 (fr)
FR (1) FR2453644B1 (fr)
GB (1) GB2046094B (fr)
IT (1) IT1148790B (fr)
NL (1) NL8002097A (fr)
SE (1) SE451427B (fr)
ZA (1) ZA802157B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042365C2 (de) * 1980-11-10 1987-01-29 Extrakta Strauss GmbH, 2000 Hamburg Flüssige, lecithinhaltige einphasige Mehrstoffsysteme und Verfahren zu ihrer Herstellung
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
EP0146243A1 (fr) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Inhibiteurs de la lipoxygénase
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) * 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
DE3621036A1 (de) * 1986-06-24 1988-01-07 Merckle Gmbh Fluessige ibuprofen-zubereitungen
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
CH673395A5 (fr) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
CA1319886C (fr) * 1987-02-03 1993-07-06 Alberto Ferro Solutions de micelles mixtes
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
EP0805684B1 (fr) * 1995-01-27 2002-06-12 The Board Of Regents, The University Of Texas System Procedes d'amelioration de l'activite therapeutique de medicaments non steroides anti-inflammatoires (nsaids) et compositions de phospholipides zwitterioniques utiles a ces fins
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
WO1997014407A1 (fr) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Administration de medicaments insolubles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
DE69908304T2 (de) * 1998-02-11 2004-02-19 Rtp Pharma Corp. Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1079808B1 (fr) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Compositions de microparticules a protection thermique et procede de sterilisation a la vapeur apres conditionnement
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
DK1105096T3 (da) 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
EP1214059B1 (fr) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Compositions particulaires, a surface modifiee, de substances biologiquement actives
CA2407027C (fr) 2000-04-20 2011-02-15 Rtp Pharma Inc. Procede ameliore destine aux particules de medicament insolubles dans l'eau
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
WO2005011708A1 (fr) 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions et methodes permettant de traiter, de prevenir et/ou d'attenuer des cancers, l'apparition de cancers ou les symptomes de cancers
US20070265344A1 (en) * 2006-02-06 2007-11-15 Pharmaceutical Solutions, Inc. Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
EP2068833B1 (fr) * 2006-07-26 2013-01-09 The Board of Regents of the University of Texas System Préparations parentérale d'anti-inflammatoires associés à des phospholipides à toxicité gi réduite, et procédés de préparation de d'utilisation de celles-ci
KR20140014350A (ko) 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 정맥 내 투여용 이부프로펜의 투여
US8871810B2 (en) * 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
CA2766367A1 (fr) * 2009-07-31 2011-02-03 Cumberland Pharmaceuticals Inc. Traitement de patients gravement atteints faisant appel a de l'ibuprofene par voie intraveineuse
FR2971712B1 (fr) * 2011-02-22 2016-06-10 Map France Solution stable de ketoprofene pour injection intraveineuse
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
DK2825039T3 (en) 2012-03-16 2017-11-27 Cumberland Pharmaceuticals Inc Injectable ibuprofen formulation
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
WO2014105655A1 (fr) 2012-12-24 2014-07-03 Neurogastrx, Inc. Méthodes de traitement d'affections du tractus digestif
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
WO2015200369A1 (fr) 2014-06-24 2015-12-30 Neurogastrx, Inc. Promédicaments de métopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044931A (en) * 1960-01-27 1962-07-17 Geigy Chem Corp Aryloxy acetic acid amides: process for parenteral application
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
JPS6320209A (ja) * 1986-07-11 1988-01-27 Mitsubishi Motors Corp 油圧サスペンシヨン装置を備える車両の車高調整方法

Also Published As

Publication number Publication date
CA1144480A (fr) 1983-04-12
BE882731A (fr) 1980-07-31
JPS55141407A (en) 1980-11-05
JPH0337524B2 (fr) 1991-06-05
ZA802157B (en) 1981-05-27
GB2046094A (en) 1980-11-12
DE2914788A1 (de) 1980-10-16
FR2453644A1 (fr) 1980-11-07
NL8002097A (nl) 1980-10-14
ATA195880A (de) 1982-06-15
FR2453644B1 (fr) 1985-07-05
AU5733180A (en) 1980-10-16
SE8002714L (sv) 1980-10-12
IT1148790B (it) 1986-12-03
GB2046094B (en) 1983-10-26
DE2914788C2 (fr) 1990-06-21
US4309421A (en) 1982-01-05
AU539044B2 (en) 1984-09-06
AT369651B (de) 1983-01-25
IT8021299A0 (it) 1980-04-10
CH642546A5 (de) 1984-04-30

Similar Documents

Publication Publication Date Title
SE451427B (sv) Parenteralt administrerbara vattenlosningar med ett fysiologiskt ph och sett att framstella dessa losningar
RU2136282C1 (ru) Концентрированный водный раствор аргатробана
ES2650665T3 (es) Método de cristalización y biodisponibilidad
AU2016219653B2 (en) Crystallization Method and Bioavailability
CA1133395A (fr) Produit pharmaceutique anti-inflamatoire oral
JP2511417B2 (ja) リポソ−ム形成用組成物および形成方法
US8252836B2 (en) Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
DE60318227T2 (de) Aggregate mit erhöhter verformbarkeit, aus mindestens drei amphiphilen bestehend, zum verbesserten transport durch teildurchlässige barrieren und zur nichtinvasiven verabreichung von medikamenten in vivo, insbesondere durch die haut
EP0574255B1 (fr) Dérivés de substances anti-inflammatoires, analgésiques et/ou anti-pyretiques non-stéroidiens, leur application et formulations pharmaceutiques qui les contiennent
BRPI0413742B1 (pt) Composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
SE451428B (sv) Injicerbar stabil vattenlosning med inflammationshemmande verkan och sett att framstella denna losning
IE50913B1 (en) Rosmarinic acid-phospholipid complexes,process for their preparation and medicines containing them
ES2392903B1 (es) Preparación inyectable de melatonina
PT1827379E (pt) Formulações contendo alquilfosfocolinas usando novos portadores de carga negativa
RU2013105783A (ru) Парентеральные составы производных элацитарабина
JPH0139406B2 (fr)
IL173330A (en) Sterilized by a filter for relief of inflammation, pain or fever and a method of preparing it
JPH02250876A (ja) ２―フェニル―１，２―ベンズイソセレナゾール―３（２ｈ）―オンの安定した非経口溶液及びその製造方法
Ioannou Arsonolipids, pseudo arsonolipids, arsinolipids and arsonoliposomes: Preparations, biophysical, biochemical and biological aspects
US5849941A (en) Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
Farooqui Formulation and development of proniosomal gel for transdermal delivery of ketorolac tromethamine
EP0319136A1 (fr) Liposomes et leur procédé de préparation
JPS6172721A (ja) インシユリン含有リポゾ−ム
DE19828097A1 (de) Kombinationspräparat von Aminohydrocarbylphosphonsäurederivaten und Hemmern des Fettstoffwechsels
ES2442450B1 (es) Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8002714-7

Effective date: 19931110

Format of ref document f/p: F